Corbus Pharmaceuticals Holdings (CRBP) Liabilities and Shareholders Equity (2013 - 2025)

Corbus Pharmaceuticals Holdings' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $168.2 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 7.9% year-over-year to $168.2 million; the TTM figure through Dec 2025 stood at $542.7 million (down 9.21% YoY), while the FY2025 annual figure was $168.2 million, up 7.9% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $168.2 million, up from $109.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $168.2 million in Q4 2025, with the low at $28.3 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $114.5 million (2021), against an average of $105.3 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 57.37% in 2023, then surged 451.35% in 2024.
• Corbus Pharmaceuticals Holdings' Liabilities and Shareholders Equity stood at $107.7 million in 2021, then sank by 38.45% to $66.3 million in 2022, then tumbled by 57.37% to $28.3 million in 2023, then soared by 451.35% to $155.9 million in 2024, then grew by 7.9% to $168.2 million in 2025.
• Business Quant data shows CRBP's Liabilities and Shareholders Equity at $168.2 million in Q4 2025, $109.5 million in Q3 2025, and $125.1 million in Q2 2025.